Canadian clinical practice guidelines for the manageme and obsessive-compulsive disorders

BMC Psychiatry

14, S1

DOI: 10.1186/1471-244x-14-s1-s1

Citation Report

#	Article	IF	CITATIONS
1	The reappraisal of benzodiazepines in the treatment of anxiety and related disorders. Expert Review of Neurotherapeutics, 2014, 14, 1275-1286.	1.4	77
2	Generalized anxiety disorder in primary care: mental health services use and treatment adequacy. BMC Family Practice, 2015, 16, 146.	2.9	32
3	Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice. Neuropsychiatric Disease and Treatment, 2015, 11, 1885.	1.0	47
4	Update on Managing Generalized Anxiety Disorder in Older Adults. Journal of Gerontological Nursing, 2015, 41, 10-20.	0.3	6
5	An Overview of Pharmacotherapy of Social Anxiety Disorder. Fuansho Kenkyu, 2015, 7, 29-39.	0.1	0
6	Pharmacotherapy of obsessive-compulsive disorder during pregnancy: a clinical approach. Revista Brasileira De Psiquiatria, 2015, 37, 334-342.	0.9	16
7	Perspective de pairs aidants sur leur expérience d'animation d'un programme d'autotraitement du trouble panique. Sante Mentale Au Quebec, 0, 40, 35-51.	0.1	1
9	Reply to the Letter to the Editor: â€~Depression symptoms in burn patients'. Burns, 2015, 41, 1895-1896.	1.1	0
10	Generalized Anxiety Disorder. New England Journal of Medicine, 2015, 373, 2059-2068.	13.9	220
13	Latest guidelines for the management of the anxiety disorders – a report from The International Anxiety Disorders Society Conference, Melbourne 2014. Australasian Psychiatry, 2015, 23, 388-391.	0.4	6
14	Impulsive aggressive obsessions following cerebellar strokes: a case study. Journal of Neurology, 2015, 262, 1775-1776.	1.8	9
15	Generalized anxiety disorder: psychopharmacotherapy update on a common and commonly overlooked condition. Australasian Psychiatry, 2015, 23, 338-342.	0.4	9
16	The POSE study - panic control treatment versus panic-focused psychodynamic psychotherapy under randomized and self-selection conditions: study protocol for a randomized controlled trial. Trials, 2015, 16, 130.	0.7	8
17	Overrepresentation of unaccompanied refugee minors in inpatient psychiatric care. SpringerPlus, 2015, 4, 131.	1.2	57
18	Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: A systematic review and meta-analysis. Journal of Psychiatric Research, 2015, 64, 88-98.	1.5	47
19	Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders. Psychiatry Research, 2015, 229, 37-48.	1.7	145
20	Papel da memantina no tratamento das perturbações da ansiedade: uma revisão baseada na evidência. Jornal Brasileiro De Psiquiatria, 2016, 65, 179-185.	0.2	0
21	Psychological factors and treatment effectiveness in resistant anxiety disorders in highly comorbid inpatients. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 1539-1551.	1.0	20

#	ARTICLE	IF	CITATIONS
22	Effectiveness of In Virtuo Exposure and Response Prevention Treatment Using Cognitive–Behavioral Therapy for Obsessive–Compulsive Disorder: A Study Based on a Single-Case Study Protocol. Frontiers in Psychiatry, 2016, 7, 99.	1.3	23
23	Pharmacokinetic patterns of risperidone-associated adverse drug reactions. European Journal of Clinical Pharmacology, 2016, 72, 1091-1098.	0.8	25
24	Benzodiazepine use associated with co-morbid post-traumatic stress syndrome and depression in older adults seeking services in general medical settings. International Psychogeriatrics, 2016, 28, 913-920.	0.6	2
26	Incentives and disincentives for treating of depression and anxiety in Ontario Family Health Teams: protocol for a grounded theory study. BMJ Open, 2016, 6, e014623.	0.8	3
27	Changes in temporal attention inhibition following prolonged exposure and sertraline in the treatment of PTSD Journal of Consulting and Clinical Psychology, 2016, 84, 415-426.	1.6	14
28	Discontinuing benzodiazepines: best practices. Epidemiology and Psychiatric Sciences, 2016, 25, 214-216.	1.8	12
29	New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Expert Review of Neurotherapeutics, 2016, 16, 483-495.	1.4	18
30	Pharmacotherapy for obsessive compulsive disorder in clinical practice – Data of 842 inpatients from the International AMSP Project between 1994 and 2012. Journal of Affective Disorders, 2016, 200, 89-96.	2.0	12
31	Sustained Use of Benzodiazepines and Escalation to High Doses in a Canadian Population. Psychiatric Services, 2016, 67, 1012-1018.	1.1	28
32	Group schema therapy versus group cognitive behavioral therapy for social anxiety disorder with comorbid avoidant personality disorder: study protocol for a randomized controlled trial. Trials, 2016, 17, 487.	0.7	19
33	The use of waitlists as control conditions in anxiety disorders research. Journal of Psychiatric Research, 2016, 83, 112-120.	1.5	48
34	Anxiety and Cardiovascular Disease Risk: a Review. Current Cardiology Reports, 2016, 18, 120.	1.3	101
35	Improving outcomes for patients with medication-resistant anxiety: effects of collaborative care with cognitive behavioral therapy. Depression and Anxiety, 2016, 33, 1099-1106.	2.0	10
36	A qualitative study of perceived needs and factors associated with the quality of care for common mental disorders in patients with chronic diseases: the perspective of primary care clinicians and patients. BMC Family Practice, 2016, 17, 134.	2.9	31
37	Anxiety. Lancet, The, 2016, 388, 3048-3059.	6.3	419
38	Potential for Drug-Drug Interactions with Adjunctive Tramadol Use in Treatment of Obsessive-Compulsive Disorder. Canadian Journal of Psychiatry, 2016, 61, 308-309.	0.9	3
39	Treatment–resistant panic disorder: a systematic review. Expert Opinion on Pharmacotherapy, 2016, 17, 159-168.	0.9	34
40	Effect of emotion regulation training in patients with panic disorder: Evidenced by heart rate variability measures. General Hospital Psychiatry, 2016, 40, 68-73.	1.2	11

#	ARTICLE	IF	Citations
41	Treating co-occurring chronic low back pain & generalized anxiety disorder. Nurse Practitioner, 2016, 41, 12-18.	0.2	6
42	Treatment-refractory posttraumatic stress disorder (TRPTSD): a review and framework for the future. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 70, 170-218.	2.5	55
43	The pattern of anxiolytic and hypnotic management by Australian general practice trainees. Drug and Alcohol Review, 2017, 36, 261-269.	1.1	8
44	Who Should Transition? Defining a Target Population of Youth with Depression and Anxiety That Will Require Adult Mental Health Care. Journal of Behavioral Health Services and Research, 2017, 44, 316-330.	0.6	22
45	Utilization of healthcare services among elderly with cognitive impairment no dementia and influence of depression and anxiety: a longitudinal study. Aging and Mental Health, 2017, 21, 810-822.	1.5	10
46	A proposal for a psychopharmacology–pharmacotherapy catalogue of learning objectives and a curriculum in Europe. World Journal of Biological Psychiatry, 2017, 18, 29-38.	1.3	13
48	No role for benzodiazepines in posttraumatic stress disorder? A surplus of certainty despite scarce evidence. Australasian Psychiatry, 2017, 25, 339-341.	0.4	4
49	Sex and gender considerations in Canadian clinical practice guidelines: a systematic review. CMAJ Open, 2017, 5, E66-E73.	1.1	47
50	Prefrontal tDCS and sertraline in obsessive compulsive disorder: a case report and review of the literature. Neurocase, 2017, 23, 173-177.	0.2	41
51	Can Long-Term Pharmacotherapy Prevent Relapses in Generalized Anxiety Disorder? A Systematic Review. Clinical Drug Investigation, 2017, 37, 737-743.	1.1	11
52	Anxiety disorders. Nature Reviews Disease Primers, 2017, 3, 17024.	18.1	345
53	Comprehensive neuropsychological evaluation of children and adolescents with sickle cell anemia: a hospital-based sample. Revista Brasileira De Hematologia E Hemoterapia, 2017, 39, 32-39.	0.7	7
54	Contemporary Psychiatry, Psychoanalysis, and Psychotherapy. Canadian Journal of Psychiatry, 2017, 62, 304-307.	0.9	1
55	Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?. Depression and Anxiety, 2017, 34, 1006-1017.	2.0	73
56	Social Anxiety Disorder. New England Journal of Medicine, 2017, 376, 2255-2264.	13.9	115
57	A 6-Year Posttreatment Follow-up of Panic Disorder Patients. Journal of Clinical Psychopharmacology, 2017, 37, 429-434.	0.7	18
58	Alcohol use disorder and depression: proposed rewording of Choosing Wisely recommendation. Cmaj, 2017, 189, E442-E443.	0.9	2
60	Virtual reality compared with (i) in vivo (i) exposure in the treatment of social anxiety disorder: A three-arm randomised controlled trial. British Journal of Psychiatry, 2017, 210, 276-283.	1.7	236

#	Article	IF	Citations
61	Pharmacological Management of Problem Gambling. SpringerBriefs in Psychology, 2017, , 85-93.	0.1	1
62	Evidence-Based Psychotherapy in Primary Care. Focus (American Psychiatric Publishing), 2017, 15, 264-270.	0.4	4
63	Support received after bereavement by suicide and other sudden deaths: a cross-sectional UK study of 3432 young bereaved adults. BMJ Open, 2017, 7, e014487.	0.8	53
64	Effect of Feeding High Gamma-Aminobutyric Acid-Containing Giant Embryo Black Sticky Rice (<i>Oryza) Tj ETQq1</i>	1.0,78431 0.8	.4 rgBT /Ov
65	Evaluation of Depression and Suicidal Patients in the Emergency Room. Psychiatric Clinics of North America, 2017, 40, 363-377.	0.7	1
66	The Treatment of Refractory Generalized Anxiety Disorder. Current Treatment Options in Psychiatry, 2017, 4, 404-417.	0.7	2
67	Management of Treatment-Resistant Posttraumatic Stress Disorder. Current Treatment Options in Psychiatry, 2017, 4, 387-403.	0.7	10
68	The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders. Current Psychiatry Reports, 2017, 19, 103.	2.1	25
69	Beta-Blockers for Exams Identify Students at High Risk of Psychiatric Morbidity. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 266-273.	0.7	15
70	Novel pharmacological treatment strategies for posttraumatic stress disorder. Expert Review of Clinical Pharmacology, 2017, 10, 167-177.	1.3	18
71	Panic attacks and panic disorder in the American Indian community. Journal of Anxiety Disorders, 2017, 48, 6-12.	1.5	9
72	Association between Internet gaming disorder and generalized anxiety disorder. Journal of Behavioral Addictions, 2017, 6, 564-571.	1.9	73
73	Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life. Frontiers in Pharmacology, 2017, 8, 259.	1.6	205
74	Surveying Psychiatrists' Psychopharmacology Practices Across Common Clinical Scenarios. Focus (American Psychiatric Publishing), 2017, 15, 445-449.	0.4	1
75	Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ: British Medical Journal, 2017, 356, j603.	2.4	147
76	Refractory social anxiety disorder. Journal of Psychiatry and Neuroscience, 2017, 42, E1-E2.	1.4	2
78	Islamic integrated exposure response therapy for mental pollution subtype of contamination obsessive-compulsive disorder: a case report and literature review. Mental Health, Religion and Culture, 2018, 21, 210-218.	0.6	8
79	Benzodiazepine prescription in Ontario residents aged 65 and over: a population-based study from 1998 to 2013. Therapeutic Advances in Psychopharmacology, 2018, 8, 99-114.	1.2	17

#	Article	IF	CITATIONS
80	Patients' characteristics and their influence on course of fear during agoraphobic symptom provocation: may SS(N)RI treatment compensate unfavorable individual preconditions?. Nordic Journal of Psychiatry, 2018, 72, 325-335.	0.7	2
81	To what extent do clinical practice guidelines respond to the needs and preferences of patients diagnosed with obsessive–compulsive disorder?. Revista Colombiana De PsiquiatrÃa (English Ed), 2018, 47, 98-107.	0.1	1
82	Association Analysis of the Brain-Derived Neurotrophic Factor Gene <i>Val66Met</i> Polymorphism and Gender with Efficacy of Antidepressants in the Chinese Han Population with Generalized Anxiety Disorder. Genetic Testing and Molecular Biomarkers, 2018, 22, 199-206.	0.3	4
83	Antidepressants versus placebo for generalised anxiety disorder (GAD). The Cochrane Library, 2018, , .	1.5	2
84	Dismantling cognitive-behaviour therapy for panic disorder: a systematic review and component network meta-analysis. Psychological Medicine, 2018, 48, 1945-1953.	2.7	139
85	Predictors of benzodiazepine use in a transdiagnostic sample of panic disorder, social anxiety disorder, and obsessive-compulsive disorder patients. Psychiatry Research, 2018, 262, 237-245.	1.7	4
86	Psychiatrists' treatment preferences for generalized anxiety disorder. Human Psychopharmacology, 2018, 33, e2643.	0.7	6
87	Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Psychological Medicine, 2018, 48, 1975-1984.	2.7	99
88	The lesser of two evils: a qualitative study of quetiapine prescribing by family physicians. CMAJ Open, 2018, 6, E191-E196.	1.1	13
89	An appraisal of the trustworthiness of practice guidelines for depression and anxiety in children and youth. Depression and Anxiety, 2018, 35, 530-540.	2.0	27
90	Yoga for anxiety: A systematic review and meta-analysis of randomized controlled trials. Depression and Anxiety, 2018, 35, 830-843.	2.0	158
91	Bipolar disorder and obsessive compulsive disorder: The comorbidity does not further impair the neurocognitive profile. Journal of Affective Disorders, 2018, 235, 1-6.	2.0	7
92	¿En qué medida las guÃas de práctica clÃnica responden a las necesidades y preferencias de los usuarios diagnosticados de trastorno obsesivo compulsivo?. Revista Colombiana De PsiquiatrÃa, 2018, 47, 98-107.	0.1	1
93	Religious-integrated therapy for religious obsessive-compulsive disorder in an adolescent: a case report and literature review. Mental Health, Religion and Culture, 2018, 21, 204-209.	0.6	6
94	Pharmacotherapy of Obsessive-Compulsive Disorder During Breastfeeding. American Journal of Therapeutics, 2018, 25, e541-e547.	0.5	4
95	Report of the 2016 Mental Health Expert Panel on suicide prevention in the Canadian Armed Forces. Journal of Military, Veteran and Family Health, 2018, 4, 70-89.	0.3	8
97	Treatment adequacy for social anxiety disorder in primary care patients. PLoS ONE, 2018, 13, e0206357.	1.1	16
98	Anxiety and Mood Disorders in Systemic Lupus Erythematosus: Current Insights and Future Directions. Current Rheumatology Reports, 2018, 20, 85.	2.1	30

#	ARTICLE	IF	CITATIONS
99	Pharmacotherapy of postpartum obsessive–compulsive disorder: a systematic review. Expert Review of Neurotherapeutics, 2018, 18, 925-931.	1.4	7
100	Benzodiazepine receptor agonist dispensations in Alberta: a population-based descriptive study. CMAJ Open, 2018, 6, E678-E684.	1.1	3
101	Staff and patient accounts of <scp>PRN</scp> medication administration and nonâ€pharmacological interventions for anxiety. International Journal of Mental Health Nursing, 2018, 27, 1834-1841.	2.1	8
102	Assessing and Treating Offenders with Mental Illness. , 2018, , 9-37.		7
103	Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. Australian and New Zealand Journal of Psychiatry, 2018, 52, 1109-1172.	1.3	137
104	A pragmatic randomized controlled trial of group transdiagnostic cognitive-behaviour therapy for anxiety disorders in primary care: study protocol. BMC Psychiatry, 2018, 18, 320.	1.1	14
105	Korean guidelines for the treatment of panic disorder. Journal of the Korean Medical Association, 2018, 61, 493.	0.1	2
106	L'union des modà les de l'intolérance à l'incertitude et de la régulation émotionnelle renforce-t le traitement cognitif-comportemental du trouble d'anxiété généralisée�. Journal De Thérapie Comportementale Et Cognitive, 2018, 28, 185-195.		1
107	Adolescent and nurse perspectives of psychotherapeutic interventions for PTSD delivered through task-shifting in a low resource setting. PLoS ONE, 2018, 13, e0199816.	1.1	8
108	Antidepressant use in older inpatients: current situation and application of the revised STOPP criteria. Therapeutic Advances in Drug Safety, 2018, 9, 373-384.	1.0	11
109	Association of Use of Omega-3 Polyunsaturated Fatty Acids With Changes in Severity of Anxiety Symptoms. JAMA Network Open, 2018, 1, e182327.	2.8	82
110	Oriental herbal medicine for generalized anxiety disorder: A systematic review of randomized controlled trials. European Journal of Integrative Medicine, 2018, 20, 36-62.	0.8	4
111	Anxiolytics. , 2018, , 73-95.		0
112	Late-Life Anxiety Disorders. , 2018, , 253-264.		1
113	Serotonergic antidepressant use and morbidity and mortality among older adults with COPD. European Respiratory Journal, 2018, 52, 1800475.	3.1	33
114	Eye movement desensitization and reprocessing as a treatment for PTSD: current neurobiological theories and a new hypothesis. Annals of the New York Academy of Sciences, 2018, 1426, 127-145.	1.8	16
115	Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opinion on Pharmacotherapy, 2018, 19, 1057-1070.	0.9	127
116	The Development of a Community Pharmacy-Based Intervention to Optimize Patients' Use of and Experience with Antidepressants: A Step-by-Step Demonstration of the Intervention Mapping Process. Pharmacy (Basel, Switzerland), 2018, 6, 39.	0.6	7

#	Article	IF	Citations
117	Patterns of benzodiazepines use in primary care adults with anxiety disorders. Heliyon, 2018, 4, e00688.	1.4	21
118	The prevalence of diagnosed obsessive compulsive disorder and associated comorbidities: A population-based Canadian study. Psychiatry Research, 2018, 268, 137-142.	1.7	50
119	Low sense of coherence is associated with anxiety among adults: Results based on data from all 47 prefectures of Japan. Comprehensive Psychiatry, 2018, 86, 131-136.	1.5	9
120	Benzodiazepine Use: The Underbelly of the Opioid Epidemic. Journal of Psychosocial Nursing and Mental Health Services, 2018, 56, 11-15.	0.3	16
121	Reduction of anxiety after treatment with transdermal clonidine. American Journal of Health-System Pharmacy, 2018, 75, 742-744.	0.5	7
122	Anxiety Disorders: From Bench to Bedside and Beyond. , 2019, , 33-58.		1
123	The Struggle of Behavioral Therapists With Exposure: Self-Reported Practicability, Negative Beliefs, and Therapist Distress About Exposure-Based Interventions. Behavior Therapy, 2019, 50, 353-366.	1.3	86
124	Trends in Prevalence and Management of Childhood Anxiety by Australian Pediatricians. Academic Pediatrics, 2019, 19, 35-43.	1.0	7
125	Posttraumatic stress disorder with secondary psychotic features (PTSD-SP): Diagnostic and treatment challenges. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 88, 265-275.	2.5	64
126	Does the addition of cognitive therapy to exposure and response prevention for obsessive compulsive disorder enhance clinical efficacy? A randomized controlled trial in a community setting. British Journal of Clinical Psychology, 2019, 58, 1-18.	1.7	24
127	Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: A network meta-analysis. Journal of Psychiatric Research, 2019, 118, 21-30.	1.5	23
128	The efficacy of group cognitive-behavioural therapy plus duloxetine for generalised anxiety disorder versus duloxetine alone. Acta Neuropsychiatrica, 2019, 31, 316-324.	1.0	8
129	Depression, antidepressants and the risk of cardiovascular events and death in older men. Maturitas, 2019, 128, 4-9.	1.0	18
130	Pharmacological treatment of obsessive compulsive disorder in adults: A clinical practice guideline based on the ADAPTE methodology. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2019, 12, 77-91.	0.2	3
131	Level of Insight in Patients With Obsessive–Compulsive Disorder: An Exploratory Comparative Study Between Patients With "Good Insight―and "Poor Insight― Frontiers in Psychiatry, 2019, 10, 413.	1.3	29
132	A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy. Current Medicinal Chemistry, 2019, 25, 5647-5661.	1.2	44
133	Approaching Cognitive Behavior Therapy For Generalized Anxiety Disorder From A Cognitive Process Perspective. Frontiers in Psychiatry, 2019, 10, 796.	1.3	11
134	Augmentation therapy of N-acetylcysteine for OCD: A meta-analysis of double-blind, randomized, placebo-controlled trials. Journal of Obsessive-Compulsive and Related Disorders, 2019, 23, 100481.	0.7	0

#	Article	IF	CITATIONS
135	Efficacy of venlafaxine extended release in major depressive disorder patients. International Clinical Psychopharmacology, 2019, 34, 110-118.	0.9	11
136	Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders., 2019, 204, 107402.		132
137	Towards precision medicine in generalized anxiety disorder: Review of genetics and pharmaco(epi)genetics. Journal of Psychiatric Research, 2019, 119, 33-47.	1.5	19
138	Therapeutic strategies for social anxiety disorder: where are we now?. Expert Review of Neurotherapeutics, 2019, 19, 1179-1189.	1.4	23
139	Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users. Journal of Psychiatric Research, 2019, 111, 134-139.	1.5	42
140	Patterns in Outpatient Benzodiazepine Prescribing in the United States. JAMA Network Open, 2019, 2, e187399.	2.8	197
141	Effect of Selective Serotonin Reuptake Inhibitors on Healthcare Utilization in Patients with Post-Traumatic Stress Disorder and Alcohol Use Disorder. Alcohol and Alcoholism, 2019, 54, 428-434.	0.9	7
142	An evaluation of large group cognitive behaviour therapy with mindfulness (CBTm) classes. BMC Psychiatry, 2019, 19, 132.	1.1	5
143	Obsessive compulsive disorder (OCD): Current treatments and a framework for neurotherapeutic research. Advances in Pharmacology, 2019, 86, 237-271.	1.2	5
144	Examining postpartum depression screening effectiveness in well child clinics in Alberta, Canada: A study using the All Our Families cohort and administrative data. Preventive Medicine Reports, 2019, 14, 100888.	0.8	9
145	The Prevalence and Risk Factors of Undiagnosed Depression and Anxiety Disorders Among Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1674-1680.	0.9	73
146	Levels and predictors of participation in integrated treatment programs for pregnant and parenting women with problematic substance use. BMC Public Health, 2019, 19, 154.	1.2	18
147	Exposure to a Standardized Catastrophic Scenario in Virtual Reality or a Personalized Scenario in Imagination for Generalized Anxiety Disorder. Journal of Clinical Medicine, 2019, 8, 309.	1.0	28
149	Combining Drug and Psychological Treatments for Obsessive- Compulsive Disorder: What is the Evidence, When and for Whom. Current Medicinal Chemistry, 2019, 25, 5632-5646.	1.2	8
150	The Association Between the Sedative Loads and Clinical Severity Indicators in the First-Onset Major Depressive Disorder. Frontiers in Psychiatry, 2019, 10, 129.	1.3	3
151	Neuromodulation Strategies in Post-Traumatic Stress Disorder: From Preclinical Models to Clinical Applications. Brain Sciences, 2019, 9, 45.	1.1	22
152	Characterisation of concurrent use of prescription opioids and benzodiazepine/Z-drugs in Alberta, Canada: a population-based study. BMJ Open, 2019, 9, e030858.	0.8	21
153	Acceptance of Anxiety through Art Therapy: A Case Report Exploring How Anthroposophic Art Therapy Addresses Emotion Regulation and Executive Functioning. Case Reports in Psychiatry, 2019, 2019, 1-13.	0.2	5

#	ARTICLE	IF	CITATIONS
154	Prescription Benzodiazepine Use in Privately Insured U.S. Children and Adolescents. American Journal of Preventive Medicine, 2019, 57, 775-785.	1.6	17
155	Scrupulosity and Islam: a perspective. Journal of Spirituality in Mental Health, 2021, 23, 255-277.	0.5	3
156	Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine. International Clinical Psychopharmacology, 2019, 34, 241-246.	0.9	8
158	Effectiveness and safety of long-term benzodiazepine use in anxiety disorders. International Clinical Psychopharmacology, 2019, 34, 211-221.	0.9	23
159	New insights and perspectives on the genetics of obsessive-compulsive disorder. Psychiatric Genetics, 2019, 29, 142-151.	0.6	16
160	Anxiety and Stress-Related Disorders and Mindfulness-Based Interventions: a Systematic Review and Multilevel Meta-analysis and Meta-Regression of Multiple Outcomes. Mindfulness, 2019, 10, 996-1005.	1.6	52
161	Assessment of Pregabalin Postapproval Trials and the Suggestion of Efficacy for New Indications. JAMA Internal Medicine, 2019, 179, 90.	2.6	24
162	Comparative efficacy and tolerability of antipsychotics as augmentations in adults with treatment-resistant obsessive-compulsive disorder: A network meta-analysis. Journal of Psychiatric Research, 2019, 111, 51-58.	1.5	14
163	Intimate Partner Sexual Violence: An Often Overlooked Problem. Journal of Women's Health, 2019, 28, 363-374.	1.5	43
164	Theranostic pharmacology in PTSD: Neurobiology and timing. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 90, 245-263.	2.5	7
165	Choosing the appropriate pharmacotherapy for obsessive-compulsive disorder in adult patients with comorbid anxiety disorders: clinical and nosological considerations. Expert Opinion on Pharmacotherapy, 2019, 20, 123-126.	0.9	2
166	Prevalence and Factors Associated With Psychiatric Medication Use in Bariatric Surgery Candidates. Psychosomatics, 2019, 60, 449-457.	2.5	8
167	Assessing the methodological quality of the Canadian Psychiatric Association's anxiety and depression clinical practice guidelines. Journal of Evaluation in Clinical Practice, 2019, 25, 613-621.	0.9	9
168	A closer look at the relationships between panic attacks, emergency department visits and non-cardiac chest pain. Journal of Health Psychology, 2019, 24, 717-725.	1.3	12
169	Calidad de las historias clÃnicas de los practicantes de un consultorio psicológico de una universidad colombiana. Educacion Medica, 2019, 20, 72-78.	0.3	0
170	Interventions to improve benzodiazepine tapering success in the elderly: a systematic review. Aging and Mental Health, 2019, 23, 411-416.	1.5	16
171	Manualized single-session behavior treatment with self-help manual for panic disorder with or without agoraphobia. Psychotherapy Research, 2020, 30, 776-787.	1.1	1
172	Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 96, 109735.	2.5	45

#	Article	IF	CITATIONS
173	Effectiveness of intensive treatment services for obsessive compulsive disorder: outcomes from the first Canadian residential treatment program. International Journal of Psychiatry in Clinical Practice, 2020, 24, 59-67.	1.2	6
174	The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap. Pharmacological Reviews, 2020, 72, 80-151.	7.1	29
175	Association between suicide death and concordance with benzodiazepine treatment guidelines for anxiety and sleep disorders. General Hospital Psychiatry, 2020, 62, 21-27.	1.2	5
176	Physical activity and blood pressure during pregnancy: Mediation by anxiety symptoms. Journal of Affective Disorders, 2020, 264, 376-382.	2.0	10
177	Panic attack provocation in panic disorder patients with a computer simulation. Journal of Affective Disorders, 2020, 264, 498-505.	2.0	5
178	Treating anxious syndromes with pregabalin in patients with psychosis. Journal of Psychiatry and Neuroscience, 2020, 45, 370-370.	1.4	1
179	Videoconferencing Psychotherapy for Panic Disorder and Agoraphobia: Outcome and Treatment Processes From a Non-randomized Non-inferiority Trial. Frontiers in Psychology, 2020, 11, 2164.	1.1	32
180	The mediating role of perceived social support between anxiety symptoms and life satisfaction in pregnant women: a cross-sectional study. Health and Quality of Life Outcomes, 2020, 18, 223.	1.0	28
181	A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine. Frontiers in Psychiatry, 2020, 11, 554899.	1.3	26
182	Pain and Interoceptive Awareness Outcomes of Chronic Pain Patients With Spinal Cord Stimulation. Neuromodulation, 2021, 24, 1357-1362.	0.4	4
183	<p>Cognitive Behavioral Therapy Reduces Benzodiazepine Anxiolytics Use in Japanese Patients with Mood and Anxiety Disorders: A Retrospective Observational Study</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2135-2142.	1.0	4
184	Does anxiety moderate the effectiveness of mirtazapine in patients with treatment-resistant depression? A secondary analysis of the MIR trial. Journal of Psychopharmacology, 2020, 34, 1342-1349.	2.0	2
185	Framing the process in the implementation of care for people with generalized anxiety disorder in primary care: a qualitative evidence synthesis. BMC Family Practice, 2020, 21, 237.	2.9	4
186	Dopaminergic System Alteration in Anxiety and Compulsive Disorders: A Systematic Review of Neuroimaging Studies. Frontiers in Neuroscience, 2020, 14, 608520.	1.4	16
187	Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Frontiers in Psychiatry, 2020, 11, 595584.	1.3	143
188	Environmental enrichment and its influence on rodent offspring and maternal behaviours, a scoping style review of indices of depression and anxiety. Pharmacology Biochemistry and Behavior, 2020, 197, 172997.	1.3	23
189	Efficacy and acceptability of cannabinoids for anxiety disorders in adults: A systematic review & Efficacy and acceptability of cannabinoids for anxiety disorders in adults: A systematic review & Efficacy and Effi	1.5	21
190	Benzodiazepine Use and Deprescribing in Belgian Nursing Homes: Results from the COMEâ€ON Study. Journal of the American Geriatrics Society, 2020, 68, 2768-2777.	1.3	16

#	Article	IF	CITATIONS
191	Literature based discovery of alternative TCM medicine for adverse reactions to depression drugs. BMC Bioinformatics, 2020, 21, 405.	1.2	6
192	Examining cognitive change in magnetic resonance-guided focused ultrasound capsulotomy for psychiatric illness. Translational Psychiatry, 2020, 10, 397.	2.4	11
193	Pharmacological treatments in panic disorder in adults: a network meta-analysis. The Cochrane Library, 0, , .	1.5	2
194	Group transdiagnostic cognitive-behavior therapy for anxiety disorders: a pragmatic randomized clinical trial. Psychological Medicine, 2022, 52, 2460-2470.	2.7	18
195	Citalopram in Treatment of Pregnant Women With Panic Disorder. Journal of Clinical Psychopharmacology, 2020, 40, 615-617.	0.7	0
196	Incidence of and Characteristics Associated With Long-term Benzodiazepine Use in Finland. JAMA Network Open, 2020, 3, e2019029.	2.8	24
197	Magnetic resonance-guided focused ultrasound capsulotomy for refractory obsessive compulsive disorder and major depressive disorder: clinical and imaging results from two phase I trials. Molecular Psychiatry, 2020, 25, 1946-1957.	4.1	53
198	Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments. Expert Review of Clinical Pharmacology, 2020, 13, 655-670.	1.3	41
199	Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. International Clinical Psychopharmacology, 2020, 35, 173-193.	0.9	70
200	Plus ça change? Benzodiazepine prescription in older patients with schizophrenia is common but best avoided. International Psychogeriatrics, 2020, 32, 419-422.	0.6	O
201	Long-term Outcomes of Intensive Inpatient Care for Severe, Resistant Obsessive-Compulsive Disorder: Résultats à long terme de soins intensifs à des patients hospitalisés pour un trouble obsessionnel-compulsif grave et résistant. Canadian Journal of Psychiatry, 2020, 65, 779-789.	0.9	11
202	Therapist beliefs about exposure therapy implementation. The Cognitive Behaviour Therapist, 2020, 13, .	0.4	3
203	Effect of Osteopathic Manipulative Therapy on Generalized Anxiety Disorder. Journal of Osteopathic Medicine, 2020, 120, 133-143.	0.4	7
204	Development of the short version of the spielberger stateâ€"trait anxiety inventory. Psychiatry Research, 2020, 291, 113223.	1.7	124
205	The Adoption of New Treatment Modalities by Health Professionals and the Relative Weight of Empirical Evidence in Favor of Virtual Reality Exposure Versus Mindfulness in the Treatment of Anxiety Disorders. Frontiers in Human Neuroscience, 2020, 14, 86.	1.0	7
206	Implementing parity for mental health and substance use treatment in Medicaid. Health Services Research, 2020, 55, 604-614.	1.0	1
207	People with obsessive-compulsive disorder often remain symptomatic following psychological treatment: A clinical significance analysis of manualised psychological interventions. Journal of Affective Disorders, 2020, 275, 94-108.	2.0	12
208	Association between Generalized Anxiety Disorder and Premenstrual Dysphoric Disorder in a Diagnostic Interviewing Study. International Journal of Environmental Research and Public Health, 2020, 17, 988.	1.2	12

#	Article	IF	CITATIONS
209	Depression, Anxiety, and Apathy in Mild Cognitive Impairment: Current Perspectives. Frontiers in Aging Neuroscience, 2020, 12, 9.	1.7	153
210	The Treatment of Suicide and Self-Injurious Behaviors in Children and Adolescents. Current Treatment Options in Psychiatry, 2020, 7, 39-52.	0.7	7
211	A Case of Comorbid PTSD and Posttraumatic OCD Treated with Sertraline-Aripiprazole Augmentation. Case Reports in Psychiatry, 2020, 2020, 1-4.	0.2	3
212	The association of physical activity and sleep duration with incident anxiety symptoms: A cohort study of 134,957 Korean adults. Journal of Affective Disorders, 2020, 265, 305-313.	2.0	8
213	Effects of Brief Depression and Anxiety Management Training on a US Army Division's Primary Care Providers. Military Medicine, 2020, 185, e719-e723.	0.4	0
214	Helping Families to Understand and Cope With Psychiatric Disorders in Childhood—Beyond Basic Facts. JAMA Psychiatry, 2020, 77, 433.	6.0	1
215	Nonmedical Benzodiazepine Use in Adolescents: Indirect Effects of Internalizing and Externalizing Symptoms. International Journal of Mental Health and Addiction, 2020, , 1.	4.4	1
216	Commentary: Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders. Frontiers in Psychiatry, 2020, 11, 264.	1.3	7
217	A systematic review of cognitive-behavioral therapy for pharmacotherapy treatment-resistant obsessive-compulsive disorder. Journal of Obsessive-Compulsive and Related Disorders, 2020, 26, 100532.	0.7	2
218	Neuroprotective effect of 25-Methoxyhispidol A against CCl4-induced behavioral alterations by targeting VEGF/BDNF and caspase-3 in mice. Life Sciences, 2020, 253, 117684.	2.0	29
219	Current pharmacotherapy for tic disorders. Expert Opinion on Pharmacotherapy, 2020, 21, 567-580.	0.9	9
220	Social Anxiety Symptoms and Quality of Life of Secondary School Students of Abha, Saudi Arabia. Journal of Genetic Psychology, 2021, 182, 18-30.	0.6	8
221	The Relative Impact of Cognitive and Behavioral Skill Comprehension and Use During CBT for Obsessive Compulsive Disorder. Cognitive Therapy and Research, 2021, 45, 439-449.	1.2	0
222	Properties of common anxiety scales among patients with bipolar disorder. Journal of Affective Disorders, 2021, 281, 972-979.	2.0	2
223	Maximizing maternal health and value for money in postpartum depression screening: a cost-effectiveness analysis using the All Our Families cohort and administrative data in Alberta, Canada. Journal of Affective Disorders, 2021, 281, 839-846.	2.0	6
224	Genetic and epigenetic architecture of Obsessive-Compulsive Disorder: In search of possible diagnostic and prognostic biomarkers. Journal of Psychiatric Research, 2021, 137, 554-571.	1.5	15
225	Identifying and Managing Anxiety Disorders in Primary Care. Journal for Nurse Practitioners, 2021, 17, 18-25.	0.4	3
226	Evaluation of Psychotropic Drug Use in Adolescents Accessing a General Emergency Medical Department for Mental Disorders. Adolescents, 2021, 1, 1-9.	0.3	O

#	Article	IF	CITATIONS
227	Pharmacological management of postâ€traumatic stress disorder and its associated nightmares: A survey of psychiatrists. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 158-165.	0.7	1
228	A pilot study of magnetic seizure therapy for treatmentâ€resistant obsessive–compulsive disorder. Depression and Anxiety, 2021, 38, 161-171.	2.0	3
229	Academic Detailing to Reduce Sedative-Hypnotic Prescribing in Older Veterans. Journal of Pharmacy Practice, 2021, 34, 287-294.	0.5	6
230	Tranquilizers/Anxiolytics: Definition, Indications, Contraindications, and Treatment., 2021,, 1-15.		0
231	Tranquilizer/Anxiolytics: Benzodiazepines (Intermediate-Acting) – Alprazolam, Bromazepam, Clonazepam, Lorazepam. , 2021, , 1-12.		0
232	Augmentation of Psychotherapy with D-Cycloserine in Patients with Anxiety Disorders. , 2021, , 1-17.		0
233	Pharmacogenetics of Obsessive-Compulsive Disorder: An Evidence-Update. Current Topics in Behavioral Neurosciences, 2021, 49, 385-398.	0.8	5
234	Physical activity and exercise for the prevention and management of anxiety., 0,, 369-384.		2
235	Tranquilizer/Anxiolytics: Pregabalin. , 2021, , 1-16.		0
236	Non-pharmacological therapies for the treatment of post-traumatic stress disorder among emergency responders: a scoping review. Revista Da Escola De Enfermagem Da U S P, 2021, 55, e03724.	0.3	3
237	The Brain-Gut Axis: Psychological Functioning and Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2021, 10, 377.	1.0	42
238	Tranquilizer/Anxiolytics: Antidepressants. , 2021, , 1-12.		0
240	Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial. Clinical and Translational Science, 2021, 14, 1359-1368.	1.5	20
241	L'Attachement dans le Trouble de Stress Post-Traumatique chez l'adulteÂ: revue de la littérature. La Presse Médicale Formation, 2021, 2, 49-57.	0.1	2
242	Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder. Journal of Clinical Psychopharmacology, 2021, 41, 172-179.	0.7	5
243	Emotional and interpersonal mechanisms in community SSRI treatment of social anxiety disorder. Journal of Psychiatry and Neuroscience, 2021, 46, E56-E64.	1.4	0
244	Does cognitive behavioral therapy for anxiety disorders assist the discontinuation of benzodiazepines among patients with anxiety disorders? A systematic review and metaâ€analysis. Psychiatry and Clinical Neurosciences, 2021, 75, 119-127.	1.0	11
245	Cognitive-behavioral therapy in pregnant women with generalized anxiety disorder: a retrospective cohort study on therapeutic efficacy, gestational age and birth weight. Revista Brasileira De Psiquiatria, 2021, 43, 61-64.	0.9	5

#	Article	IF	CITATIONS
246	Medicinal Plants in the Treatment of Obsessive-Compulsive Disorder: A Review. Current Drug Discovery Technologies, 2021, 18, 8-16.	0.6	4
247	Smart-Glass Guided Exposure for Anxiety Disorders: A Proof-of-Concept Study. Cognitive and Behavioral Practice, 2021, 28, 364-378.	0.9	5
248	Relationship between clozapine dose and severity of obsessive-compulsive symptoms. Medical Hypotheses, 2021, 148, 110506.	0.8	1
249	What Is the Impact of COVID-19 Pandemic on Patients with Pre-Existing Mood or Anxiety Disorder? An Observational Prospective Study. Medicina (Lithuania), 2021, 57, 304.	0.8	17
250	Impact of anxiety and depression disorders on sustained return to work after work-related musculoskeletal strain or sprain: a gender stratified cohort study. Scandinavian Journal of Work, Environment and Health, 2021, 47, 296-305.	1.7	3
251	Binge eating disorder hidden behind a wall of anxiety disorders. , 2021, 46, E208-E209.		1
252	Binge eating disorder hidden behind a wall of anxiety disorders. Journal of Psychiatry and Neuroscience, 2021, 46, E208-E209.	1.4	1
253	Blended Acceptance and Commitment Therapy Versus Face-to-face Cognitive Behavioral Therapy for Older Adults With Anxiety Symptoms in Primary Care: Pragmatic Single-blind Cluster Randomized Trial. Journal of Medical Internet Research, 2021, 23, e24366.	2.1	20
254	Mental Health of Men in Later Life. , 2021, , 251-262.		0
255	Determining the Efficacy of Electronic Cognitive Behavioral Therapy for Generalized Anxiety Disorder Compared to Pharmaceutical Interventions: Protocol for a Quasi-Experimental Study. JMIR Research Protocols, 2021, 10, e27772.	0.5	0
256	Relationship between benzodiazepine prescription, aggressive behavior, and behavioral disinhibition: a retrospective study in a Swiss prison. Harm Reduction Journal, 2021, 18, 58.	1.3	1
257	Expanding conceptual understanding of interview anxiety and performance: Integrating cognitive, behavioral, and physiological features. International Journal of Selection and Assessment, 2021, 29, 234-252.	1.7	16
258	Serotonin Reuptake Inhibitors and the Gut Microbiome: Significance of the Gut Microbiome in Relation to Mechanism of Action, Treatment Response, Side Effects, and Tachyphylaxis. Frontiers in Psychiatry, 2021, 12, 682868.	1.3	20
259	Different Attitudes of Patients and Psychiatrists Toward Benzodiazepine Treatment. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 1927-1936.	1.0	1
260	Inequities in the delivery of mental health care: a grounded theory study of the policy context of primary care. International Journal for Equity in Health, 2021, 20, 144.	1.5	6
261	Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Focus (American) Tj ETQq1 1 (0.784314	rgBT /Overlo
262	Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder. Psychiatry Research, 2021, 300, 113853.	1.7	7
263	Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance. Focus (American Psychiatric Publishing), 2021, 19, 145-160.	0.4	9

#	Article	IF	CITATIONS
264	Overwhelmed by Bodily Sensations. Physician Assistant Clinics, 2021, 6, 515-526.	0.1	1
265	Anxiolytic-like effect of natural product 2-hydroxy-3,4,6-trimethoxyacetophenone isolated from Croton anisodontus in adult zebrafish via serotonergic neuromodulation involvement of the 5-HT system. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 2023-2032.	1.4	7
266	Trauma and post-traumatic stress disorder in patients treated for opioid use disorder: findings from a 12-month cohort study. BJPsych Open, 2021, 7, .	0.3	4
267	Interventions to reduce benzodiazepine and sedative-hypnotic drug use in acute care hospitals: A scoping review. Research in Social and Administrative Pharmacy, 2022, 18, 2874-2886.	1.5	4
268	Treatment of depression: Are psychotropic drugs appropriately dosed in women and in the elderly? Dosages of psychotropic drugs by sex and age in routine clinical practice. Human Psychopharmacology, 2022, 37, e2809.	0.7	5
269	Evidence-Based Pharmacotherapy of Generalised Anxiety Disorder: Focus on Agomelatine. Advances in Therapy, 2021, 38, 52-60.	1.3	2
270	Usages et bon usage des benzodiazépines anxiolytiques et hypnotiques. Annales Medico-Psychologiques, 2021, 179, 748-756.	0.2	4
271	Tackling the global problem of traumatic stress in low-income countries: a pilot clinical trial comparing reconsolidation therapy to paroxetine in Nepal. BMC Psychiatry, 2021, 21, 434.	1.1	2
272	Treatment adequacy and remission of depression and anxiety disorders and quality of life in primary care older adults. Health and Quality of Life Outcomes, 2021, 19, 218.	1.0	8
273	Cognitive Behavior Therapy Targeting Intolerance of Uncertainty Versus Selective Serotonin Reuptake Inhibitor for Generalized Anxiety Disorder: A Randomized Clinical Trial. Behaviour Change, 2021, 38, 250-262.	0.6	12
274	Theory and Practice of Treatment of Concurrent Major Depressive and Alcohol Use Disorders: 7 Lessons from Clinical Practice and Research. Canadian Journal of Addiction, 2021, 12, 39-46.	0.2	0
275	Treatment Guidelines for PTSD: A Systematic Review. Journal of Clinical Medicine, 2021, 10, 4175.	1.0	58
276	Association between anxiety symptoms and atrial fibrillation in a community cohort of Chinese older adults: a case-control study. BMC Cardiovascular Disorders, 2021, 21, 471.	0.7	4
277	Effects of music therapy on anxiety: A meta-analysis of randomized controlled trials. Psychiatry Research, 2021, 304, 114137.	1.7	22
278	Transcranil‡al magnetil‡c stil‡mulatil‡on over orbil‡tofrontal cortex in obsessil‡ve compulsil‡ve dil‡sorder: A double-blind placebo-controlled tril‡al. Journal of Obsessive-Compulsive and Related Disorders, 2021, 31, 100687.	0.7	3
279	The effects of a single session of mindful exercise on anxiety: A systematic review and meta-analysis. Mental Health and Physical Activity, 2021, 21, 100403.	0.9	12
280	Persistence of antidepressant use among refugee youth with common mental disorder. Journal of Affective Disorders, 2021, 294, 831-837.	2.0	4
281	Heart rate variability: A biomarker of selective response to mindfulness-based treatment versus fluoxetine in generalized anxiety disorder. Journal of Affective Disorders, 2021, 295, 1087-1092.	2.0	2

#	Article	IF	CITATIONS
282	The quality and clinical applicability of recommendations in anxiety disorders guidelines: A systematic review of seventeen guidelines from seven countries. Journal of Affective Disorders, 2021, 295, 1301-1309.	2.0	2
283	Assessment of prevalence of Anxiety in adult populationÂand development of anxiety scale: A study of 819 patients with anxiety disorder. Pakistan Journal of Medical Sciences, 2021, 37, 472-476.	0.3	1
284	Pharmacological Treatment of Panic Disorder with Non-Selective Drugs., 2016,, 289-301.		1
285	Antidepressants: Indications, Contraindications, Interactions, and Side Effects., 2020, , 1-38.		3
287	Current Research on Complementary and Alternative Medicine (CAM) in the Treatment of Anxiety Disorders: An Evidence-Based Review. Advances in Experimental Medicine and Biology, 2020, 1191, 415-449.	0.8	15
289	Off-label use of antipsychotics and associated factors in community living older adults. Aging and Mental Health, 2019, 23, 158-165.	1.5	7
290	Easing the disruption of COVID-19: supporting the mental health of the people of Canada—October 2020—an RSC Policy Briefing. Facets, 2020, 5, 1071-1098.	1.1	18
291	Introducing a practical tool to reduce fear and anxiety during COVID-19. Canadian Pharmacists Journal, 2021, 154, 26-29.	0.4	2
292	Obsessive-Compulsive Disorder. CONTINUUM Lifelong Learning in Neurology, 2018, 24, 828-844.	0.4	20
293	A Qualitative Study on Incentives and Disincentives for Care of Common Mental Disorders in Ontario Family Health Teams. Healthcare Policy, 2016, 12, 84-96.	0.3	4
294	Topiramate augmentation in a patient with obsessive–compulsive disorder. Journal of Psychiatry and Neuroscience, 2015, 40, E31-E32.	1.4	5
295	N-Acetylcysteine augmentation in refractory obsessive–compulsive disorder. Journal of Psychiatry and Neuroscience, 2019, 44, 215-216.	1.4	3
296	Treatments for Anxiety Disorders in Malaysia. The Malaysian Journal of Medical Sciences, 2019, 26, 24-36.	0.3	3
297	Prevalence and Determinants of Long-Term Utilization of Antidepressant Drugs: A Retrospective Cohort Study. Neuropsychiatric Disease and Treatment, 2020, Volume 16, 1157-1170.	1.0	12
298	The 2014 Survey on Living with Chronic Diseases in Canada on Mood and Anxiety Disorders: a methodological overview. Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice, 2016, 36, 275-288.	0.8	12
299	Use of medication and psychological counselling among Canadians with mood and/or anxiety disorders. Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice, 2017, 37, 160-171.	0.8	7
300	Anxiety Disorder in Children: Review. Journal of Paediatric Care Insight, 2016, 1, 18-28.	0.0	6
301	Korean Guidelines for the Pharmacological Treatment of Social Anxiety Disorder: Initial Treatment Strategies. Psychiatry Investigation, 2018, 15, 147-155.	0.7	4

#	Article	IF	Citations
302	The Association between Physical Activity and Anxiety Symptoms for General Adult Populations: An Analysis of the Dose-Response Relationship. Psychiatry Investigation, 2020, 17, 29-36.	0.7	19
303	A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive–compulsive disorder in children/adolescents and adults. Health Technology Assessment, 2016, 20, 1-392.	1.3	84
304	Clinical practice guidelines for geriatric anxiety disorders. Indian Journal of Psychiatry, 2018, 60, 371.	0.4	28
305	Effect of <i>Beta vulgaris </i> Linn. leaves extract on anxiety- and depressive-like behavior and oxidative stress in mice after acute restraint stress. Pharmacognosy Research (discontinued), 2016, 8, 1.	0.3	46
306	Social anxiety disorder in Saudi adolescent boys: Prevalence, subtypes, and parenting style as a risk factor. Journal of Family and Community Medicine, 2016, 23, 25.	0.5	22
307	Clinical Practice Guidelines for Cognitive-Behavioral Therapies in Anxiety Disorders and Obsessive-Compulsive and Related Disorders. Indian Journal of Psychiatry, 2020, 62, 230.	0.4	21
308	An observational study comparing the efficacy of duloxetine and pregabalin in patients with generalized anxiety disorder. Engrami, 2020, 42, 20-31.	0.1	3
309	Treatment of posttraumatic stress disorder: Focus on pharmacotherapy. Mental Health Clinician, 2019, 9, 373-382.	0.5	25
310	Comparative efficacy and acceptability of psychotherapies for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. British Journal of Psychiatry, 2022, 221, 507-519.	1.7	20
311	Yoga as an Integrative Therapy for Mental Health Concerns: An Overview of Current Research Evidence. Psychiatry International, 2021, 2, 386-401.	0.5	3
312	A systematic review and meta-analysis of acceptance- and mindfulness-based interventions for DSM-5 anxiety disorders. Scientific Reports, 2021, 11, 20385.	1.6	30
313	The German Guidelines for the treatment of anxiety disorders: first revision. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 571-582.	1.8	25
314	Drug Management of Psychiatric Co-morbidity in Multiple Sclerosis. Neuropsychiatric Symptoms of Neurological Disease, 2015, , 95-103.	0.3	0
315	Anxiety $\hat{a} \in \r$ Is There an App for That? Considering Technology, Psychiatry, and Internet-Assisted Cognitive Behavioral Therapy. , 0, , .		0
316	Pharmacological Treatment with the Selective Serotonin Reuptake Inhibitors., 2016,, 223-236.		0
317	Effects of ascorbic acid on anxiety state and affect in a non-clinical sample. Acta Neurobiologiae Experimentalis, 2017, 77, 362-372.	0.4	10
318	National Clinical Guidelines. , 2017, , .		2
319	Obsessive-Compulsive Disorder (OCD). , 2017, , .		0

#	Article	IF	Citations
320	Novel trends in treatment of obsessive-compulsive disorder. Psychiatrie Pro Praxi, 2017, 18, 114-119.	0.0	1
321	Current trends in treatment of anxiety disorders. Psychiatrie Pro Praxi, 2017, 18, 106-113.	0.0	O
322	Late-Life Anxiety Disorders, Obsessive-Compulsive and Related Disorders, and Trauma- and Stressor-Related Disorders., 2018, , 109-129.		0
323	Exposure Therapy by Virtual Reality and Its Monitoring by Biofeedback. Cognitive Remediation Journal, 2018, 7, 4-9.	0.0	0
324	A Complex Case of Opiates and Related Pathologies. , 2018, , 67-78.		0
325	The Use of Transcranial Magnetic Stimulation (TMS) for Obsessive-Compulsive Disorder (OCD). , 2019, , 277-293.		0
326	Economic evaluations of commonly used structured psychotherapies for major depressive disorder and generalized anxiety disorder: A systematic review Canadian Psychology, 2018, 59, 301-314.	1.4	2
327	Exposure Therapy for Functional GI Disorders. , 2019, , 143-174.		0
328	Using VR for Obsessive-Compulsive and Related Disorders. Virtual Reality Technologies for Health and Clinical Applications, 2019, , 103-130.	0.8	1
329	Adolescents and Adults with ASD and Obsessive Compulsive Disorder. , 2019, , 67-75.		0
332	Psychologische Frühinterventionen. , 2019, , 189-216.		5
333	Clinical Study of Morphine Combined with Prednisone in the Treatment of Carcinomatous Neuralgia with Anxiety and Depression. Advances in Clinical Medicine, 2019, 09, 554-558.	0.0	0
334	Effect of salvia Officinalis L. and Rosmarinus Officinalis L. leaves extracts on anxiety and neural activity. Bioinformation, 2019, 15, 172-178.	0.2	9
335	Tratamiento farmacológico del trastorno obsesivo-compulsivo en adultos: una guÃa de práctica clÃnica basada en el método ADAPTE. Revista De PsiquiatrÃa Y Salud Mental, 2019, 12, 77-91.	1.0	5
336	Treating psychiatric symptoms and disorders with non-psychotropic medications. Dialogues in Clinical Neuroscience, 2019, 21, 193-201.	1.8	0
337	Generalized anxiety disorder: advances in neuroimaging studies. Revista Brasileira De Psiquiatria, 2019, 41, 279-279.	0.9	2
338	Randomized Controlled Trials and the Efficacy of Psychotropic Medications. , 2020, , 1-56.		0
339	Attribution Retraining Group Therapy and SSRIs Affect Differing Facets of Anxiety Among Chinese Patients with Various Diagnoses: A Single-Center, Prospective Study., 2020, 30, 97.		0

#	ARTICLE	IF	CITATIONS
340	Neuropsychological Disorders and their Nanocarriers. Current Pharmaceutical Design, 2020, 26, 2247-2256.	0.9	3
341	Current trends in treatment of generalised anxiety disorder. Psychiatrie Pro Praxi, 2020, 21, 66-72.	0.0	0
342	Risk of long-term benzodiazepine and Z-drug use following the first prescription among community-dwelling adults with anxiety/mood and sleep disorders: a retrospective cohort study. BMJ Open, 2021, 11, e046916.	0.8	5
343	Anxiety Disorders in Women. , 2020, , 111-123.		0
344	The Treatment of Adult ADHD: Complexity at Hand. , 2020, , 307-345.		1
345	Angststörungen. , 2020, , 327-353.		O
346	Mental Health in Burn Survivors. , 2021, , 147-164.		2
347	Genişletilmiş Benlik Kuramı Bağlamında Nomofobi. İnsan Ve Toplum Bilimleri Araştırmaları Dergisi, 3853-3873.	2020, 9,	2
348	Impact of arthritis on the perceived need and use of mental healthcare among Canadians with mental disorders: nationally representative cross-sectional study. BMJ Open, 2020, 10, e041371.	0.8	0
349	Anxiolytics: Misuse, Dependence, and Withdrawal Syndromes. , 2021, , 1-26.		O
350	Benzodiazepine use in Sao Paulo, Brazil. Clinics, 2020, 75, e1610.	0.6	5
351	Adult ADHD in Trauma- and Stressor-Related Disorders. , 2020, , 201-215.		0
352	Effectiveness of cognitive behavioral therapy on social anxiety disorder: A comparative study. Industrial Psychiatry, 2020, 29, 76.	0.3	2
353	Latency to selective serotonin reuptake inhibitor vs benzodiazepine treatment in patients with panic disorder: a naturalistic study. CNS Spectrums, 2023, 28, 46-52.	0.7	1
354	Driving performance assessments for benzodiazepine receptor agonist–related impairment: a scoping review protocol. JBI Evidence Synthesis, 2021, 19, 242-250.	0.6	2
355	Management of treatment-resistant generalized anxiety disorder. Mental Health Clinician, 2020, 10, 326-334.	0.5	16
357	Potential effects of rational prescribing on national health care spending: More than half a billion dollars in annual savings. Canadian Family Physician, 2016, 62, 235-44.	0.1	7
358	A Qualitative Study on Incentives and Disincentives for Care of Common Mental Disorders in Ontario Family Health Teams. Healthcare Policy, 2016, 12, 84-96.	0.3	6

#	Article	IF	CITATIONS
360	Prescribing Practices of Quetiapine for Insomnia at a Tertiary Care Inpatient Child and Adolescent Psychiatry Unit: A Continuous Quality Improvement Project. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2017, 26, 98-103.	0.7	9
361	Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. Canadian Family Physician, 2018, 64, 339-351.	0.1	113
363	Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment. Ontario Health Technology Assessment Series, 2019, 19, 1-199.	3.0	17
364	Adherence to prescription guidelines for medical cannabis in disability claimants. Canadian Family Physician, 2019, 65, e339-e343.	0.1	1
365	The association of catechol-O-methyltransferase (COMT) rs4680 polymorphisms and generalized anxiety disorder in the Chinese Han population. International Journal of Clinical and Experimental Pathology, 2020, 13, 1712-1719.	0.5	0
366	Serotonin Syndrome in Children and Adolescents Exposed to Selective Serotonin Reuptake Inhibitors - A Review of Literature. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2021, 30, 156-164.	0.7	1
367	Internet-Delivered Cognitive Behavioural Therapy for Post-traumatic Stress Disorder or Acute Stress Disorder: A Health Technology Assessment. Ontario Health Technology Assessment Series, 2021, 21, 1-120.	3.0	30
368	Online narrative exposure therapy for parents of children with neurodevelopmental disabilities suffering from posttraumatic stress symptoms – study protocol of a randomized controlled trial. Högre Utbildning, 2021, 12, 1991650.	1.4	2
369	Artificial Intelligence in Digital Mental Health. Advances in Psychology, Mental Health, and Behavioral Studies, 2022, , 201-225.	0.1	1
370	Perceived Need for Mental Health Care and Associated Factors and Outcomes in Older Adults Consulting in Primary Care. Canadian Journal of Psychiatry, 2022, 67, 553-564.	0.9	4
371	The effects of COVIDâ€19 on the dispensing rates of antidepressants and benzodiazepines in Canada. Depression and Anxiety, 2022, 39, 156-162.	2.0	14
372	Effectiveness of noninvasive brain stimulation in the treatment of anxiety disorders: a meta-analysis of sham or behaviour-controlled studies. Journal of Psychiatry and Neuroscience, 2021, 46, E592-E614.	1.4	14
373	Psychische Belastungen in der prÄ k linischen Notfallversorgung. Notfallmedizin Up2date, 2021, 16, 405-422.	0.0	0
374	Anthropophobia (Taijin Kyofusho) beyond the Boundaries of a Culture-Bound Syndrome: A Case Series from India. Indian Journal of Psychological Medicine, 2022, 44, 615-617.	0.6	3
375	Chemokine profile in women with moderate to severe anxiety and depression during pregnancy. BMC Pregnancy and Childbirth, 2021, 21, 807.	0.9	22
376	Cost-effectiveness and cost-utility of an Acceptance and Commitment Therapy intervention vs. a Cognitive Behavioral Therapy intervention for older adults with anxiety symptoms: A randomized controlled trial. PLoS ONE, 2022, 17, e0262220.	1.1	3
377	A Preliminary Study of Different Treatment Strategies for Anxious Depression. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 11-18.	1.0	0
378	"You can't un-ring the bell― a mixed methods approach to understanding veteran and family perspectives of recovery from military-related posttraumatic stress disorder. BMC Psychiatry, 2022, 22, 37.	1.1	5

#	Article	IF	CITATIONS
379	Differential Effects of Anxiety on Internet Gaming Disorder: A Large-Scale Cross-Sectional Survey. Frontiers in Psychiatry, 2021, 12, 802513.	1.3	2
380	Efficacy of Artificial Intelligence-Assisted Psychotherapy in Patients With Anxiety Disorders: A Prospective, National Multicenter Randomized Controlled Trial Protocol. Frontiers in Psychiatry, 2021, 12, 799917.	1.3	4
381	Depression, Anxiety, and Patterns of Mental Health Care Among Men With Prostate Cancer Receiving Androgen Deprivation Therapy. Oncologist, 2022, 27, 314-322.	1.9	9
382	Comparative safety of chronic versus intermittent benzodiazepine prescribing in older adults: A population-based cohort study. Journal of Psychopharmacology, 2022, 36, 460-469.	2.0	11
383	Innate immune stimulation prevents the development of anxiety-like behaviors in chronically stressed mice. Neuropharmacology, 2022, 207, 108950.	2.0	2
384	Promise unfulfilled: Implementing webâ€based psychological therapy in routine cancer care, a qualitative study of oncology health professionals' attitudes. Psycho-Oncology, 2022, 31, 1127-1135.	1.0	4
385	6. Useful Treatment Guide of Depression and Anxiety in Primary Care. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 585-592.	0.0	0
387	The theatre of depression: a role for physical therapy. Physiotherapy Theory and Practice, 2023, 39, 1325-1341.	0.6	2
388	Beyond the †normal†worries: detection and treatment of perinatal anxiety and anxiety disorders. BJ Psych Advances, 2023, 29, 187-197.	0.5	3
389	A pragmatic randomized controlled trial of a group self-management support program versus treatment-as-usual for anxiety disorders: study protocol. BMC Psychiatry, 2022, 22, 135.	1.1	1
390	N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 117, 110550.	2.5	5
391	A Case for Translation From the Clinic to the Laboratory. Perspectives on Psychological Science, 2022, 17, 1120-1149.	5.2	7
392	Strategies to improve access to cognitive behavioral therapies for anxiety disorders: A scoping review. PLoS ONE, 2022, 17, e0264368.	1.1	3
393	Minimally Adequate Treatment for Depression and Anxiety Associated With Mortality in Primary Care Older Adults. Canadian Journal of Psychiatry, 2022, 67, 669-678.	0.9	2
394	Health care system and patient costs associated with receipt of minimally adequate treatment for depression and anxiety disorders in older adults. BMC Psychiatry, 2022, 22, 175.	1.1	4
395	Child ADHD and anxiety: Parent mental health literacy and information preferences. Child and Family Social Work, 2022, 27, 665-678.	0.6	0
397	Using phytopharmaceuticals in the management of chronic stress. Praktické LékárenstvÃ, 2022, 18, 42-47.	0.0	0
398	Longitudinal patterns of comorbidity between anxiety, depression and binge eating symptoms among patients with obesity: A path analysis. Journal of Affective Disorders, 2022, 303, 255-263.	2.0	5

#	Article	IF	CITATIONS
399	Psychotherapy in Psychiatry. Canadian Journal of Psychiatry, 2021, 66, 999-1004.	0.9	4
400	Posttraumatic Stress Disorder and Anxiety-Related Conditions. CONTINUUM Lifelong Learning in Neurology, 2021, 27, 1738-1763.	0.4	7
401	Evidence of Delayed, Recursive Benefits of Self-Affirmation on Anxiety in Socially Anxious University Students. Journal of Social and Clinical Psychology, 2021, 40, 534-561.	0.2	0
402	Part I: Interactive case: Adverse effects associated with antipsychotic therapy. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 1618-1623.	0.5	0
403	Obsessive-Compulsive Disorders. CONTINUUM Lifelong Learning in Neurology, 2021, 27, 1764-1784.	0.4	4
404	Genetics of social anxiety disorder: a systematic review. Psychiatric Genetics, 2022, 32, 37-66.	0.6	3
405	Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder. International Journal of Neuropsychopharmacology, 2022, 25, 283-292.	1.0	5
406	Group autonomy enhancing treatment versus cognitive behavioral therapy for anxiety disorders: A clusterâ€randomized clinical trial. Depression and Anxiety, 2022, 39, 134-146.	2.0	2
407	Recent Advances in Anxiety Disorders and Cardiovascular Diseases. Advances in Clinical Medicine, 2022, 12, 2638-2644.	0.0	0
408	Obsessive-compulsive disorder and recalcitrant emotion: relocating the seat of irrationality. Philosophical Psychology, 0, , 1-26.	0.5	2
409	Tolerability of duloxetine in elderly and in non-elderly adults: a protocol of a systematic review and individual participant data meta-analysis of randomized placebo-controlled trials. Systematic Reviews, 2022, 11, 71.	2.5	0
415	Celecoxib versus placebo as an adjunct to treatment-as-usual in children and youth with obsessive–compulsive disorder: protocol for a single-site randomised quadruple-blind phase II study. BMJ Open, 2022, 12, e054296.	0.8	2
416	Virtual Reality and Psychedelics for the Treatment of Psychiatric Disease: A Systematic Literature Review, 2020, 17, 365-380.		4
417	Potential of a cognitive-behavioural approach to improve patient symptoms in a primary care setting. Canadian Family Physician, 2022, 68, 93-96.	0.1	0
420	Best practices for CBT treatment of taboo and unacceptable thoughts in OCD. The Cognitive Behaviour Therapist, 2022, 15 , .	0.4	3
421	Cognitive-Behavioral Therapy for Panic Disorder in Patients with Stable Coronary Artery Disease: A Feasibility Study. Journal of Clinical Psychology in Medical Settings, 2023, 30, 28-42.	0.8	2
422	Representation of Benzodiazepines in Treatment Guidelines: The Paradox of Undesirable Objectivity. Psychotherapy and Psychosomatics, 2022, 91, 295-299.	4.0	5
423	Insights into patient characteristics and documentation of the use of sedative-hypnotic/anxiolytics in primary care: a retrospective chart review study., 2022, 23, 111.		0

#	Article	IF	CITATIONS
424	Neuropsychiatry's Role in the Postacute Sequelae of COVID-19: Report From the American Neuropsychiatric Association Committee on Research. Journal of Neuropsychiatry and Clinical Neurosciences, 2022, 34, 341-350.	0.9	4
425	Protocol for a Pragmatic Trial of Pharmacotherapy Options Following Unsatisfactory Initial Treatment in OCD (PROCEED). Frontiers in Psychiatry, 2022, 13, .	1.3	O
426	Trajectories of Depression, Post-Traumatic Stress, and Chronic Pain Among Women Who Have Separated From an Abusive Partner: A Longitudinal Analysis. Journal of Interpersonal Violence, 2023, 38, 1540-1568.	1.3	7
427	Pre-existing anxiety and depression disorders and return to work after musculoskeletal strain or sprain: a phased-based approach. Journal of Occupational Rehabilitation, 0, , .	1.2	0
428	An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol. PLoS ONE, 2022, 17, e0269772.	1.1	5
429	Efficacy and safety studies review of Teraligen usage in psychiatric practice and general medicine. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 55.	0.1	2
430	Eye movement desensitisation and reprocessing: part 1 \hat{a} \in "theory, procedure and use in PTSD. BJ Psych Advances, 0, , 1-10.	0.5	1
431	The Development and Impact of Anxiety With Migraines: A Narrative Review. Cureus, 2022, , .	0.2	2
432	Using Artificial Intelligence to Enhance Ongoing Psychological Interventions for Emotional Problems in Real- or Close to Real-Time: A Systematic Review. International Journal of Environmental Research and Public Health, 2022, 19, 7737.	1.2	9
433	Calm Down With Kava: What Clinicians Need to Know. Journal of Psychosocial Nursing and Mental Health Services, 2022, 60, 17-24.	0.3	1
434	Psychological Outcomes and Interventions for Individuals With Congenital Heart Disease: A Scientific Statement From the American Heart Association. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, .	0.9	27
435	Now I Always have to Perform Well! Effects of CBT for Social Anxiety Disorder on Negative Interpretations of Positive Social Events. Cognitive Therapy and Research, 2022, 46, 1126-1136.	1.2	1
436	3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder (PTSD) in adults. The Cochrane Library, 2022, 2022, .	1.5	0
437	Effects of group mindfulness-based cognitive therapy and group cognitive behavioural therapy on symptomatic generalized anxiety disorder: a randomized controlled noninferiority trial. BMC Psychiatry, 2022, 22, .	1.1	4
438	Reduced death anxiety and obsessive beliefs as mediators of the therapeutic effects of psychedelics on obsessive compulsive disorder symptomology. Clinical Psychologist, 0, , 1-16.	0.5	4
439	Valproate Adjuvant Cognitive Behavioral Therapy in Panic Disorder Patients With Comorbid Bipolar Disorder: Case Series and Review of the Literature. Psychiatry Investigation, 2022, 19, 614-625.	0.7	3
440	Relation between anxiety disorders in adolescent mothers and dental fear in children. International Journal of Paediatric Dentistry, 0, , .	1.0	1
441	Use of pharmacological treatment for posttraumatic stress disorder: Analysis of a psychiatric population in Switzerland and comparison with international guidelines. L'Encephale, 2022, , .	0.3	1

#	Article	IF	CITATIONS
442	Systematic literature review of human studies assessing the efficacy of cannabidiol for social anxiety. Psychiatry Research Communications, 2022, 2, 100074.	0.2	5
443	Review of Evidence. , 2020, , 43-C4.P78.		0
444	Mental health in adults with 22q11.2 deletion syndrome. , 2022, , 322-337.		0
445	Anxiety Screening among the General Population of Latvia and Associated Factors. Medicina (Lithuania), 2022, 58, 1163.	0.8	1
446	An Exploratory Study of a Novel Combined Therapeutic Modality for Obsessive-Compulsive Disorder. Brain Sciences, 2022, 12, 1309.	1,1	2
447	Non-pharmacologic and pharmacologic treatments for anxiety in long-term care: a systematic review and meta-analysis. Age and Ageing, 2022, 51, .	0.7	3
449	Experiences of Patients and Therapists Testing a Virtual Reality Exposure App for Symptoms of Claustrophobia: Mixed Methods Study. JMIR Mental Health, 2022, 9, e40056.	1.7	4
450	Measuring anxiety: reliability and validity of the Turkish version of the Generalized Anxiety Disorder Scale and its relationship with academic and mental health outcomes. Mental Health, Religion and Culture, 0, , 1-12.	0.6	1
451	Moving beyond first-line treatment options for OCD. Mental Health Clinician, 2022, 12, 300-308.	0.5	0
452	Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial. Communications Medicine, 2022, 2, .	1.9	17
453	Antidepressants: Indications, Contraindications, Interactions, and Side Effects., 2022, , 1135-1172.		0
454	Augmentation of Psychotherapy with D-Cycloserine in Patients with Anxiety Disorders. , 2022, , 2243-2259.		0
455	Tranquilizer/Anxiolytics: Antidepressants. , 2022, , 2071-2082.		0
456	Anxiolytics: Misuse, Dependence, and Withdrawal Syndromes., 2022,, 2217-2242.		1
457	Randomized Controlled Trials and the Efficacy of Psychotropic Medications., 2022,, 305-359.		0
458	Tranquilizer/Anxiolytics: Pregabalin. , 2022, , 2083-2097.		0
459	Integrative Care Planning. , 2022, , 123-146.		0
460	Tranquilizers/Anxiolytics: Definition, Indications, Contraindications, and Treatment., 2022, , 2037-2051.		0

#	Article	IF	CITATIONS
461	Tranquilizer/Anxiolytics: Benzodiazepines (Intermediate-Acting) $\hat{a} \in \text{``Alprazolam, Bromazepam, Clonazepam, Lorazepam.'}$, 2022, , 2171-2183.		0
462	Alcohol use disorder with comorbid anxiety disorder: a case report and focused literature review. Addiction Science & Clinical Practice, 2022, 17, .	1.2	2
463	Psychotherapies and digital interventions for OCD in adults: What do we know, what do we need still to explore?. Comprehensive Psychiatry, 2022, , 152357.	1.5	1
465	Attitudes and Difficulties Associated with Benzodiazepine Discontinuation. International Journal of Environmental Research and Public Health, 2022, 19, 15990.	1.2	1
466	Psychological interventions for post-traumatic stress injuries among public safety personnel: a systematic review and meta-analysis. Systematic Reviews, 2022, 11, .	2.5	2
467	Lactobacillus delbrueckii reduces anxiety-like behavior in zebrafish through a gut microbiome – brain crosstalk. Neuropharmacology, 2023, 225, 109401.	2.0	6
468	Lipid and Polymeric Nanoparticles: Successful Strategies for Nose-to-Brain Drug Delivery in the Treatment of Depression and Anxiety Disorders. Pharmaceutics, 2022, 14, 2742.	2.0	10
469	CBT treatment delivery formats for panic disorder: a systematic review and network meta-analysis of randomised controlled trials. Psychological Medicine, 2023, 53, 614-624.	2.7	5
470	Protocol for a multi-site randomized controlled trial of a stepped-care intervention for emergency department patients with panic-related anxiety. BMC Psychiatry, 2022, 22, .	1.1	0
471	Nano and Microemulsions for the Treatment of Depressive and Anxiety Disorders: An Efficient Approach to Improve Solubility, Brain Bioavailability and Therapeutic Efficacy. Pharmaceutics, 2022, 14, 2825.	2.0	10
473	How We Got Here: The Demise of Psychotherapy Clinical Trials in America. American Journal of Psychotherapy, 2022, 75, 148-150.	0.4	0
474	Update on treatments for anxiety-related disorders. Current Opinion in Psychiatry, 0, Publish Ahead of Print, .	3.1	6
475	New frontiers in the pharmacological treatment of social anxiety disorder in adults: an up-to-date comprehensive overview. Expert Opinion on Pharmacotherapy, 2023, 24, 207-219.	0.9	0
476	The applicability and efficacy of Micro-Video Psychological Training Camp in groups with mild to moderate symptoms of depression and anxiety: A prospective and randomized controlled trial protocol. Frontiers in Psychiatry, 0, 13, .	1.3	0
477	Pharmacological modulation of conditioned fear in the fear-potentiated startle test: a systematic review and meta-analysis of animal studies. Psychopharmacology, 2023, 240, 2361-2401.	1.5	4
479	CO2 reactivity as a biomarker of exposure-based therapy non-response: study protocol. BMC Psychiatry, 2022, 22, .	1.1	1
480	Cognitive behavioral therapy (CBT) plus attention bias modification (ABM) reduces anxiety sensitivity and depressive symptoms in panic disorder: Aâpilot randomized trial. Scandinavian Journal of Psychology, 2023, 64, 390-400.	0.8	2
481	Cost-effectiveness of transdiagnostic group cognitive behavioural therapy for anxiety disorders <i>>v.</i> > treatment as usual: economic evaluation of a pragmatic randomized controlled trial over an 8-month time horizon using self-reported data. Psychological Medicine, 2023, 53, 6570-6582.	2.7	4

#	Article	IF	CITATIONS
482	Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials. European Archives of Psychiatry and Clinical Neuroscience, 2023, 273, 1615-1628.	1.8	2
483	Breathwork Interventions for Adults with Clinically Diagnosed Anxiety Disorders: A Scoping Review. Brain Sciences, 2023, 13, 256.	1.1	5
485	Early outcomes, associated factors and predictive values of clinical outcomes of tandospirone in generalized anxiety disorder: a post-hoc analysis of a randomized, controlled, multicenter clinical trial. Current Medical Research and Opinion, 2023, 39, 597-603.	0.9	0
486	L'anxiété chez les enfants et les adolescents – partie 2 : la prise en charge des troubles anxieux. Paediatrics and Child Health, 2023, 28, 52-59.	0.3	0
487	To Predict, Prevent, and Manage Post-Traumatic Stress Disorder (PTSD): A Review of Pathophysiology, Treatment, and Biomarkers. International Journal of Molecular Sciences, 2023, 24, 5238.	1.8	14
488	Commentary: Midbrain projection to the basolateral amygdala encodes anxiety-like but not depression-like behaviors. Frontiers in Molecular Neuroscience, $0,16,.$	1.4	0
489	Therapies for obsessive-compulsive disorder: Current state of the art and perspectives for approaching treatment-resistant patients. Frontiers in Psychiatry, 0, 14 , .	1.3	3
490	Availability of Safe and Effective Therapeutic Options to Pregnant and Lactating Individuals Following the United States Food and Drug Administration Pregnancy and Lactation Labeling Rule. Journal of Pediatrics, 2023, 259, 113342.	0.9	1
491	Anxiety in children and youth: Part 2â€"The management of anxiety disorders. Paediatrics and Child Health, 2023, 28, 60-66.	0.3	1
492	In-person 1-day cognitive behavioral therapy-based workshops for postpartum depression: a randomized controlled trial. Psychological Medicine, 2023, 53, 6888-6898.	2.7	3
494	Nanosystems, Drug Molecule Functionalization and Intranasal Delivery: An Update on the Most Promising Strategies for Increasing the Therapeutic Efficacy of Antidepressant and Anxiolytic Drugs. Pharmaceutics, 2023, 15, 998.	2.0	5
496	Trends and correlates of concurrent opioid and benzodiazepine and/or gabapentinoid use among Ontario nursing home residents. Journal of the American Geriatrics Society, 2023, 71, 2462-2475.	1.3	0
497	The treatment of post-traumatic nightmares requires more attention. Drugs and Therapy Perspectives, 2023, 39, 125-130.	0.3	1
498	Finding help for OCD in Australia: development and evaluation of a clinician directory. Australian Psychologist, 2023, 58, 190-197.	0.9	1
499	Reappraising the Relationship Between Interview Anxiety and Performance Outcome in a Computer-Mediated Setting. Business and Professional Communication Quarterly, 0, , 232949062311606.	0.3	0
509	Cognitive outcomes following functional neurosurgery in refractory OCD patients: a systematic review. Neurosurgical Review, 2023, 46, .	1.2	0
518	Brain Mechanisms Underlying Panic Attack and Panic Disorder. Neuroscience Bulletin, 0, , .	1.5	0
524	Neurodevelopmental disorders. , 2023, , .		0

ARTICLE IF CITATIONS

Anxiety and Fear-Related Disorders: Social Anxiety Disorder and Specific Phobia. , 2023, , 1-35.